An observational study in Colo-rectal Cancer, sponsored by Guardant Health, Inc.. Recruiting at 83 sites in United States. Open to participants aged 45 Years to 81 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Guardant Health, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,123 studies in Colonic Neoplasms with a site in United States — 115 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.
Among the 1,123 studies in Colonic Neoplasms with a site in United States, this one is the 19th largest by planned enrollment of the 181 observational ones that give a count, is one of 33 that started in 2025, is one of 181 observational ones, reaches primary completion later than 174 of the 187 other live ones, and was the 1,070th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →115 of the 1,123 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Puerto Rico
Ages 18+
Solstice Oncology, Inc. · Sites in United States, Belgium, Italy and 3 more countries
Ages 18+
LTZ Therapeutics, Inc. · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18+
Guardant Health, Inc. · Sites in United States
Ages 45–75 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 45 Years to 81 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,123 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 353 · Phase 2 341 · Phase 3 87 · Phase 4 10
First in 1981; this study’s year is marked. 33 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,375 is above the median of 227 across 555 observational studies indexed under Colonic Neoplasms.
Median enrollment 50 across the 865 interventional studies, 220 across the 181 observational. Of the 840 that completed or were terminated, 241 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
229 of 1,123 have an industry lead sponsor. The 10 most frequent:
Guardant Health, Inc. is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
Guardant Health, Inc. has 3 studies filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
60 of the studies in Colonic Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03803553Phase 3Massachusetts General HospitalIdentification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | 2026-12 |
| NCT06191185University of California, San FranciscoIMProving Adherence to Colonoscopy Through Teams and Technology | 2026-11-27 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
| NCT07224464New Phase Ltd.The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. | 2026-12 |
| NCT00582621Memorial Sloan Kettering Cancer CenterAscertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | 2026-12 |
Add all 60 to your calendar (.ics) → With an account.
Among the 1,123 studies in Colonic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC using colonoscopy as the reference method.
Colorectal cancer (CRC) is the fourth most diagnosed cancer and second leading cause of cancer-related death in the US, with an estimated 53,010 deaths attributable to CRC in 2024. The risk of CRC increases with age, with the majority of cases and deaths occurring in individuals aged 65 years or older. While the incidence of CRC in Americans 65 years of age or older has decreased over the last decade, the incidence of CRC in younger Americans aged 55 years or younger has been increasing since the mid-1990s. CRC disproportionately affects minority populations, with American Indian/Alaska Native and Black/African American populations having the highest incidence and mortality rates1; this is further exacerbated by systemic barriers to current CRC screening options.
CRC primarily arises from a precursor lesion, the adenomatous polyp (i.e., adenoma), that grows from the epithelial cells of the colorectal mucosa. Adenomas that grow larger than 10 mm or have elements indicating a risk of malignant transformation (e.g., high-grade dysplasia or villous features) are defined as advanced adenomas (AAs). The vast number of adenomas, even those with features classifying them as AAs, do not progress into a colorectal malignancy. Colonoscopy cannot always distinguish adenomas or advanced adenomas from other polyp histology; thus, polypectomy is routinely performed for lesions identified on endoscopy. The transition rate from adenoma onset to CRC development is estimated to be 12.5 to 25 years. This slow transition from adenoma onset to CRC onset allows for multiple CRC screening opportunities over a lifetime, providing the ability to intervene along the disease development course and the potential to detect and remove adenomas, prevent colorectal cancer, and reduce CRC incidence and subsequently, disease mortality.
Once CRC has developed, tumor staging is consistent with other solid tumors and defined based on how far the cancer has spread within the body. In Stage 0 (carcinoma in situ), the cancer cells are only in the colorectal mucosa. In Stage I, the cancer has spread to the muscular layer of the colorectum but not to nearby tissue or lymph nodes. In Stage II, the cancer has grown through the wall of the colorectum and potentially to nearby tissues but has not spread to nearby lymph nodes. In Stage III, the cancer has spread to nearby lymph nodes but not to distant parts of the body. In Stage IV, the cancer has spread to one or more distant parts of the body. The estimated time frame from CRC onset to a symptomatic diagnosis of CRC is estimated to be 4-5 years, in the absence of early detection through asymptomatic cancer screening. Tumor size and location can influence the rate of transition through the stages of CRC. The 5-year survival rate for localized disease (Stage I-II) is 91%, and is 72% for regional disease (Stage III), while the 5-year survival for metastatic disease (Stage IV) is only 14%. These statistics highlight the ability to reduce CRC-related mortality by detection of early-stage (Stage I-III) disease where therapeutic intervention has the potential to result in a cure.
Subjects age 45 to 81 at average risk of CRC who meet inclusion, do not meet exclusion criteria, and who successfully enroll in the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Positive result on another colorectal cancer screening method within the last six months, or:
Personal history of any of the following high-risk conditions for colorectal cancer:
Other hereditary cancer syndromes including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects age 45 to 81 at average risk of CRC who meet inclusion, do not meet exclusion criteria, and who successfully enroll in the study.
Diagnostic Test: Shield Blood Test for colo-rectal cancer Screening
Shield Blood Test for colo-rectal cancer Screening
Performance measures of the Shield test will be assessed for the second testing interval
* Advanced Neoplasia Specificity * AA Sensitivity * CRC Sensitivity * PPV for: CRC, AA, and advanced neoplasia. * NPV for: CRC and advanced neoplasia
Time frame: 33-42 Months Post-Enrollment
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Sep 2030, 61 months after the start.
Of 225 observational studies under Colonic Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 116. This study's planned 61 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guardant Health, Inc.